Plus, we will explore future breakthroughs that could change how cataracts are treated forever
US patent 2276508, Nabenhauer FP, "Method for the separation of optically active alpha-methylphenethylamine", published 17 March 1942, assigned to Smith Kline French 1 2 "Approved Treatments for Attention Deficit Hyperactivity Disorder: Amphetamine (Adderall), Methylphenidate (Ritalin), and Atomoxetine (Straterra)"
The courtyard is so peaceful and relaxing
Serious but rare adverse effects require particular vigilance: Acute pancreatitis : Patients should be counselled to seek immediate medical attention if they experience severe, persistent abdominal pain radiating to the back
About 62% of adults who have taken GLP-1 drugs say they took them to treat a chronic condition including diabetes or heart disease, while about 4 in 10 say they took them primarily to lose weight
The gap between the nominal patent expiration date and actual generic entry which can span anywhere from zero to six-plus years depending on litigation outcomes is where most of the analytical uncertainty lives
